Marker Assisted Selective ThErapy in Rare Cancers: Knowledge Database Establishing registrY Asia

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorNational Cancer Center, Japan

About this trial

This is a registry study that aims to collect patients' data with advanced-stage rare cancer in Asia-Pacific region. Data includes clinical information, details of treatment, prognosis, pathological diagnosis and genetic biomarkers by next-generation sequencing.

The relationship between cancer types and prognosis, the effect of treatments, and the cancer type-specific incidence of genomic alterations will be investigated to discover more specific and effective treatment.

Eligibility criteria

Qualifiers

Patients with a histological diagnosis of rare cancer, cancer of unknown primary origin, or cancer of rare tissue subtypes of common cancers. (Defined in protocol.)

Patients with Advanced stage cancer.

Disqualifiers

None

Trial design

Treatments tested in this trial

  • Genomic sequence

Treatment groups

1,000 Participants
are divided into 2 treatment groups

Sponsors and collaborators